Prevention of p53 degradation in human MCF-7 cells by proteasome inhibitors does not mimic the action of roscovitine

Annals of the New York Academy of Sciences

Volumn 1090, Issue , 2006, Pages 234-244

  Ranftler, Carmen ^a   Gueorguieva, Marieta ^a   Wȩsierska Ga̧dek, Jòzefa ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; CDK inhibitors; Cell cycle regulation; Depolarization of mitochondria; G2 arrest; Inhibitors of cyclin dependent kinases; p53 phosphorylation; p53 stability; p53 tumor suppressor

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLINE; PROTEASOME INHIBITOR; PROTEIN P53; ROSCOVITINE; SERINE; PROTEASOME; PROTEINASE INHIBITOR; PURINE DERIVATIVE;

CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; STEADY STATE; UPREGULATION; ARTICLE; CELL CYCLE; CHEMISTRY; DRUG ANTAGONISM; FLOW CYTOMETRY; HYDROLYSIS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

CELL CYCLE; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; HYDROLYSIS; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PURINES; SERINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247627400     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1378.026     Document Type: Conference Paper

References (26)

1. LEVINE, A.J. 1992. The p53 tumour suppressor gene and product. Cancer Surv. 12: 59-79.
2. MOLL, U.M., G. RIOU & A.J. LEVINE. 1992. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. 89: 7262-7266.
3. MOMAND, J., G.P. ZAMBETTI, D.C. OLSON, et al. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
4. OREN, M. 2003. Decision making by p53: life, death and cancer. Cell Death Differ. 10: 431-442.
5. KUBBUTAT, M.H.G., S.N. JONES & K.H. VOUSDEN. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
6. JIMENEZ, G.S., S.H. KHAN, J.M. STOMMEL & G.M. WAHL. 1999. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18: 7656-7665.
7. APPELLA, E. & C.W. ANDERSON. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764-2772.
8. LI, M., C. LUO, C.L. BROOKS & W. GU. 2002. Acetylation of p53 inhibits ubiquitination by Mdm2. J. Biol. Chem. 277: 50607-50611.
9. WESIERSKA-GADEK, J., J. WOJCIECHOWSKI, C. RANFTLER & G. SCHMID. 2005. Role of p53 suppressor in ageing: regulation of transient cell cycle arrest and terminal senescence. J. Physiol. Pharmacol. 56: 15-28.
10. WESIERSKA-GADEK, J. & M. HORKY. 2003. How the nucleolar sequestration of p53 protein or its interplayers contributes to its (re)-activation. Ann. N. Y. Acad. Sci. 1010: 266-272.
11. LJUNGMAN, M. 2000. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 3: 208-225.
12. EL-DEIRY, W.S., T. TOKINO, V.E. VELCULESCU, et al. 1993. WAF1, a potential mediator of p53 suppression. Cell 75: 817-825.
13. HAUPT, S., M. BERGER, Z. GOLDBERG & Y. HAUPT. 2003. Apoptosis-the p53 network. J. Cell Sci. 116: 4077-4085
14. WESIERSKA-GADEK, J., J. WOJCIECHOWSKI & G. SCHMID. 2003. Central and carboxyterminal regions of human p53 protein are essential for interaction and complex formation with PARP-1. J. Cell Biochem. 89: 220-232.
15. WESIERSKA-GADEK, J., J. WOJCIECHOWSKI & G. SCHMID. 2003. Phosphorylation regulates the interaction and complex formation between wt p53 protein and PARP-1. J. Cell Biochem. 89: 1260-1284.
16. LJUNGMAN, M., F. ZHANG, F. CHEN, et al. 1999. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18: 583-592.
17. WESIERSKA-GADEK, J. & G. SCHMID. 2000. Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G1 checkpoint. J. Cell Biochem. 80: 85-103.
18. VINDELOV, L.L., I.J. CHRISTENSEN & N.J. NISSEN. 1983. Adetergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327.
19. WESIERSKA-GADEK, J., D. SCHLOFFER, V. KOTALA & M. HORKY. 2002. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int. J. Cancer 101: 128-136.
20. WESIERSKA-GADEK, J., E. BOHRN, Z. HERCEG, et al. 2000. Differential susceptibility of normal and PARP knock-out mouse fibroblasts to proteasome inhibitors. J. Cell Biochem. 78: 681-696.
21. WESIERSKA-GADEK, J., D. SCHLOFFER, M. GUEORGUIEVA, et al. 2004. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res. 64: 4487-4497.
22. WESIERSKA-GADEK, J. & G. SCHMID. 2006. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell cycle progression and activation of wild-type p53 protein. Expert Opin. Investi. Drugs 15: 23-38.
23. WESIERSKA-GADEK, J., M. GUEORGUIEVA, J. WOJCIECHOWSKI & M. HORKY. 2004. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine. Pol. J. Pharmacol. 56: 635-641.
24. WOJCIECHOWSKI, J., M. HORKY, M. GUEORGUIEVA & J. WESIERSKA-GADEK. 2003. Rapid onset of nucleolar disintegration preceding the cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int. J. Cancer 106: 486-495.
25. WESIERSKA-GADEK, J., M. GUEORGUIEVA & M. HORKY. 2005. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol. Cancer Ther. 4: 113-124.
26. CHEN, F., D. CHANG, M. GOB, et al. 2000. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ. 11: 239-246.